SELLAS Life Sciences Group (FRA:RXK3) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RXK3 SELLAS Life Sciences Group Inc FRA:RXK3
25 GF Score
Price €11.65
View Full Analysis

What is SELLAS Life Sciences Group FFO?

FFO (Funds from operations) only applies to REITs.

FRA:RXK3
25GF Score
SELLAS Life Sciences Group Inc FRA:RXK3
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SELLAS Life Sciences Group Business Description

Other Exchanges SLS:USA
Address 7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score

Get the complete analysis for FRA:RXK3

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.65
Price